Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25675225 | 0.95 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL25675223 | 0.95 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL25675220 | 0.95 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL8745553 | 0.82 | ALDH1A1 (0.39) | CXCR2CFD | |
| SCHEMBL17696548 | 0.76 | PDK1 (0.36) | CXCR2 | |
| SCHEMBL17696544 | 0.76 | PDK1 (0.36) | CXCR2 | |
| SCHEMBL25072101 | 0.76 | CXCR2 (0.37) | CXCR2CFD | |
| SCHEMBL6561841 | 0.76 | CXCR2 (0.40) | CXCR2CFD | |
| Carbamic Acid SCHEMBL17961682 | 0.73 | CXCR2 (0.36) | CXCR2CFD | |
| SCHEMBL11036864 | 0.71 | CXCR2 (0.38) | CXCR2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307376-B1 | NOVEL PHENYLAMINO ISONICOTINAMIDE COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-11-04 | — | — | EP | disclosed |
| US-8889719-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889719-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889719-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20130184314-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184314-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184314-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-8404725-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404725-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404725-B2 | Phenylamino isonicotinamide compounds | MERCK PATENT GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20110184032-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110184032-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110184032-A1 | Novel Phenylamino Isonicotinamide Compounds | MERCK PATENT GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| WO-2010017051-A1 | NOVEL PHENYLAMINO ISONICOTINAMIDE COMPOUNDS | MERCK SERONO S.A. (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184032-A1 | Novel Phenylamino Isonicotinamide Compounds | MKI67, FGFR1, IGF1R | CXCR2 254/4885CFD 4527/4885 |
| US-20130184314-A1 | Novel Phenylamino Isonicotinamide Compounds | MKI67, FGFR1, IGF1R | CXCR2 254/4885CFD 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.